{"denoms":[{"counts":[{"groupId":"BG000","value":"587"}],"units":"Participants"}],"groups":[{"description":"Lenalidomide administered orally, 25 mg daily (QD) for the first 21 days of each 28-day cycle. Pulse dexamethasone administered orally, 40 mg daily on Days 1-4, 9-12, and 17-20 for each 28-day cycle during Cycles 1 to 4 (approximately months 1-4). Beginning with Cycle 5 (approximately month 5), a maintenance dose of dexamethasone (40 mg QD) was administered on Days 1 to 4 of each 28-day cycle.","id":"BG000","title":"Lenalidomide Plus Dexamethasone"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.74","value":"64.5"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"<=18 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"314"}]}],"title":">18 and <=65 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"273"}]}],"title":">65 years"}],"paramType":"NUMBER","title":"Age, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"241"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"346"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"548"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"17"}]}],"title":"Other"},{"categories":[{"measurements":[{"groupId":"BG000","value":"10"}]}],"title":"Asian / Pacific Islander"},{"categories":[{"measurements":[{"groupId":"BG000","value":"9"}]}],"title":"Black"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"Hispanic"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"participant"}]}